A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung Cancer
Clinical trial NCT07256509 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07256509
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-11-30
- Primary completion
- 2026-11-30
- Enrollment
- 120
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.